Develops an investigational cancer medicine for patients with ovarian cancer and other cancers.
10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and…View ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
−$28.8MView ↗
A narrower development focus
The older report described several drug candidates, discovery programs and studies across a range of cancers. The latest report centers development on azenosertib, focused on platinum-resistant ovarian cancer, with other tumor types as further opportunities.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 26, 2026Azenosertib (ZN-c3), a potentially first-in-class Wee1 inhibitor for advanced solid tumors and hematological malignancies; ZN-d5, a B-cell…View ↗
We are currently evaluating azenosertib and ZN-d5 in multiple ongoing clinical trials and conducting studies to enable an Investigational…View ↗
Rapidly advance the clinical development of our potentially best-in-class and first-in-class Wee1 inhibitor, azenosertib, toward regulatory…View ↗
Competes with Debiopharm Research & Manufacturing, Bristol-Myers Squibb, Aprea Therapeutics, Schrödinger, Acrivon Therapeutics, Impact Therapeutics, Shouyao Holdings, WuXi AppTec, and Wigen Biomedicine Technology (Shanghai)
10-K for FY2025, filed Mar 26, 2026Currently, there are no WEE1 inhibitors approved by the FDA. Debiopharm Research & Manufacturing SA has disclosed that it is clinically…View ↗
Loading...